

# ACR–ACNM–SNMMI–SPR PRACTICE PARAMETER FOR THE PERFORMANCE OF GASTROINTESTINAL TRACT, HEPATIC, AND SPLENIC SCINTIGRAPHY

The American College of Radiology, with more than 40,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields.

The American College of Radiology will periodically define new practice parameters and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice parameters and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each practice parameter and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review and approval. The practice parameters and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized.

## PREAMBLE

This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care<sup>1</sup>. For these reasons and those set forth below, the American College of Radiology and our collaborating medical specialty societies caution against the use of these documents in litigation in which the clinical decisions of a practitioner are called into question.

The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the practitioner considering all the circumstances presented. Thus, an approach that differs from the guidance in this document, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in this document when, in the reasonable judgment of the practitioner, such course of action is indicated by variables such as the condition of the patient, limitations of available resources, or advances in knowledge or technology after publication of this document. However, a practitioner who employs an approach substantially different from the guidance in this document may consider documenting in the patient record information sufficient to explain the approach taken.

The practice of medicine involves the science, and the art of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to the guidance in this document will not assure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The purpose of this document is to assist practitioners in achieving this objective.

---

<sup>1</sup> *Iowa Medical Society and Iowa Society of Anesthesiologists v. Iowa Board of Nursing*, 831 N.W.2d 826 (Iowa 2013) Iowa Supreme Court refuses to find that the "ACR Technical Standard for Management of the Use of Radiation in Fluoroscopic Procedures (Revised 2008)" sets a national standard for who may perform fluoroscopic procedures in light of the standard's stated purpose that ACR standards are educational tools and not intended to establish a legal standard of care. See also, *Stanley v. McCarver*, 63 P.3d 1076 (Ariz. App. 2003) where in a concurring opinion the Court stated that "published standards or guidelines of specialty medical organizations are useful in determining the duty owed or the standard of care applicable in a given situation" even though ACR standards themselves do not establish the standard of care.

## I. INTRODUCTION

This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the Society for Pediatric Radiology (SPR).

This practice parameter is intended to guide physicians performing and interpreting gastrointestinal tract, hepatic, and splenic scintigraphy in adult and pediatric patients. Gastrointestinal scintigraphy involves the intravenous (IV), oral, transcatheter (to include enteric tubes), or intraperitoneal administration of a radiopharmaceutical that localizes in or transits the salivary glands, gastrointestinal tract, or peritoneal cavity. Hepatic and splenic scintigraphy involves IV administration of radiopharmaceuticals that localize in the reticuloendothelial system (RES) or blood pool of the liver and/or spleen. Imaging is performed with a gamma camera and may also include additional hybrid scintigraphic and anatomical imaging, such as single-photon emission computed tomography (SPECT) with or without computed tomography (CT) imaging, which assists with further localization of an abnormality [1]. As with all scintigraphic studies, correlation of findings with the results of other imaging and nonimaging procedures, as well as clinical information, is necessary to achieve maximum diagnostic yield.

Imaging of the hepatobiliary system is discussed separately in the [ACR-ACNM-SNMMI-SPR Practice Parameter for the Performance of Hepatobiliary Scintigraphy](#) [2]. Imaging of radiopharmaceuticals delivered via the hepatic artery in preparation for yttrium-90 (<sup>90</sup>Y) radioembolization of primary and metastatic liver tumors is discussed separately in the [ACR-ABS-ACNM-ASTRO-SIR-SNMMI Practice Parameter for Selective Internal Radiation Therapy \(SIRT\) or Radioembolization for Treatment of Liver Malignancies](#) [3].

Application of this practice parameter should be in accordance with the [ACR-ACNM-SNMMI-SPR Practice Parameter for the Use of Radiopharmaceuticals in Diagnostic Procedures](#) [4].

## II. INDICATIONS

Clinical indications are varied and include, but are not limited to, the following:

### A. Gastrointestinal Tract

1. Salivary Gland
  - a. Demonstration of salivary gland function and/or tumors
2. Gastrointestinal Transit
  - a. Verification of suspected aspiration
  - b. Evaluation and quantification of esophageal motility
  - c. Evaluation of gastroesophageal and enterogastric reflux
  - d. Quantification of gastric emptying of solid and/or liquid meals
3. Gastrointestinal Bleeding
  - a. Demonstration of the presence and site of acute gastrointestinal bleeding
  - b. Detection of ectopic functioning gastric mucosa as seen in Meckel's diverticulum
4. Peritoneum
  - a. Assessment of peritoneovenous shunt patency
  - b. Detection of congenital or acquired perforation of the diaphragm (pleuroperitoneal fistula)
  - c. Demonstration of the presence or absence of peritoneal loculations prior to intraperitoneal chemotherapy or radiopharmaceutical therapy

### B. Liver and Spleen

1. Assessing the size, shape, and position of the liver and/or spleen
2. Differentiation of hepatic or splenic hemangiomas and other mass lesions, such as focal nodular hyperplasia (FNH)
3. Evaluating for residual or ectopic functioning splenic tissue and suspected functional asplenia

For information on radiation risks to the fetus, see the [ACR-SPR Practice Parameter for Imaging Pregnant or](#)

### III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL

See the [ACR-ACNM-SNMMI-SPR Practice Parameter for the Use of Radiopharmaceuticals in Diagnostic Procedures](#) [4].

### IV. SPECIFICATIONS OF THE EXAMINATION

The written or electronic request for gastrointestinal, hepatic, and splenic scintigraphy should provide sufficient information to demonstrate the medical necessity of the examination and allow for the proper performance and interpretation of the examination.

Documentation that satisfies medical necessity includes 1) signs and symptoms and/or 2) relevant history (including known diagnoses). The provision of additional information regarding the specific reason for the examination or a provisional diagnosis would be helpful and may at times be needed to allow for the proper performance and interpretation of the examination.

The request for the examination must be originated by a physician or other appropriately licensed health care provider. The accompanying clinical information should be provided by a physician or other appropriately licensed health care provider familiar with the patient's clinical problem or question and consistent with the state scope of practice requirements. (ACR Resolution 35 adopted in 2006 – revised in 2016, Resolution 12-b)

#### A. Radiopharmaceuticals

Several radiopharmaceuticals are currently available. The radiopharmaceutical used should be chosen based on the clinical indications and circumstances. Administered activity for children should be based on body weight and should be as low as reasonably achievable (ALARA) for diagnostic image quality as outlined in the *2016 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities* [6]. In the United States, technetium-99m (Tc-99m) sulfur colloid (SC) is the only FDA-approved agent for oral administration, and the additional radiopharmaceuticals mentioned below for oral administration may require specific radioactive licensing amendments.

##### 1. Gallium-67 Citrate (Ga-67)

Ga-67 is not commonly used and is not first line, but it is an alternative radiopharmaceutical in certain circumstances when others are not available. Given orally, Ga-67 is not absorbed from the gastrointestinal tract and may be used as a liquid-phase marker of gastric emptying. Like indium-111 (In-111) diethylenetriamine-penta-acetic acid (DTPA), this radiopharmaceutical can be used with a concomitant solid meal labeled with Tc-99m SC for gastric imaging and measurement of small-bowel or colon transit. Its long half-life (physical half-life: 78.3 hours) allows extended imaging of the abdomen up to 96 hours or longer. Administered activity is typically 0.056 kBq/kg (0.0015 mCi/kg) for dual-phase gastric emptying examinations in pediatric patients. For adults needing evaluation of colonic transit or liquid gastric emptying, a dosage of 3 to 7 MBq (0.08-0.2 mCi) can be used [7,8]. For a liquid-only gastric emptying examination, Tc-99m SC should be used instead of Ga-67 to reduce radiation exposure.

##### 2. In-111 DTPA

Given orally, with an administered activity of 5.55 to 18.5 MBq (0.15-0.50 mCi), In-111 DTPA may be used to evaluate liquid gastric emptying when a concomitant solid meal labeled with Tc-99m SC is used. Also, due to its longer half-life (physical half-life: 67.3 hours), additional imaging of the abdomen is possible up to 72 hours for measurement of small-bowel or colon transit. Administered activity of In-111 DTPA in water for colon transit is 3.7 to 37 MBq (0.1-1.0 mCi) [9-11]. However, for a liquid-only gastric examination, Tc-99m SC should be used instead of In-111 DTPA to reduce radiation exposure.

##### 3. Tc-99m (Stannous - Sn) DTPA

Given orally, Tc-99m DTPA may be used for liquid gastric emptying evaluation or for small-bowel

transit when only a single liquid meal transit examination is performed. It cannot be used simultaneously for a combined liquid- and solid-phase gastric emptying examination when a Tc-99m solid-phase radiopharmaceutical is also used. When dual-phase (solid and liquid) gastrointestinal examinations are performed, In-111 DTPA (or Ga-67 citrate) is used to measure the liquid phase, and Tc-99m SC is used for the solid phase. Tc-99m DTPA in water can also be used for esophageal transit time evaluation. The administered activity for Tc-99m DTPA is 18.5 to 37 MBq (0.5-1.0 mCi) for adults. The administered activity of the radiopharmaceutical and the volume to be fed to the pediatric patient should be based on patient factors such as age, body weight, and the usual feeding volume [12].

#### 4. Tc-99m Macroaggregated Albumin (MAA)

Given intraperitoneally, Tc-99m MAA is not absorbed and is used as a qualitative marker of the movement of ascitic fluid through peritoneovenous shunt devices or congenital/traumatic diaphragmatic fenestrations. The usual adult administered activity is 18.5 to 185 MBq (0.5-5.0 mCi) in 3 to 5 mL of 0.9% saline [12].

#### 5. Tc-99m Red Blood Cells (RBCs)

Tc-99m RBCs remain intravascular and are commonly used for detecting and localizing the source of an active gastrointestinal bleed. The usual adult IV-administered activity for gastrointestinal blood loss detection is 555 to 1,100 MBq (15-30 mCi) [13]. For pediatric patients, the recommended administered activity is 11.39 to 26.67 MBq/kg (0.31-0.72 mCi/kg). The highest RBC-labeling efficiency is achieved with the in vitro method (> 97%), which is recommended and widely used [15]. See the [ACR-ACNM-SNMMI-SPR Practice Parameter for the Use of Radiopharmaceuticals in Diagnostic Procedures](#) for handling of radiolabeled cells [4].

The usual IV-administered activity of Tc-99m-labeled autologous RBCs for hepatic hemangioma evaluation ranges from 740 to 925 MBq (20-25 mCi).

#### 6. Tc-99m RBCs (autologous and heat-damaged)

Autologous RBCs are radiolabeled, preferably by the in vitro method, with an activity of 37 to 222 MBq (1-6 mCi) for planar imaging or 555 to 1,110 MBq (15-20 mCi) for SPECT or SPECT/CT imaging and heated for 15 minutes in a preheated water bath between 49.0°C and 50.0°C. After cooling to at least body temperature, the heat-damaged RBCs are administered intravenously (IV), with imaging performed 20 to 30 minutes postinjection. The heat-damaged RBCs will be preferentially sequestered by splenic tissue. See the [ACR-ACNM-SNMMI-SPR Practice Parameter for the Use of Radiopharmaceuticals in Diagnostic Procedures](#) [4] for handling of radiolabeled cells.

#### 7. Tc-99m Sodium Pertechnetate

During the first 1 or 2 minutes after IV administration, Tc-99m sodium pertechnetate may be used as a blood flow and blood pool marker. Within minutes after injection, this radiopharmaceutical begins to concentrate normally in the salivary glands and in mucin-producing cells of the gastric mucosa, making it suitable for evaluation of salivary gland function and for detection of ectopic gastric mucosa. The usual adult IV-administered activity is 296 to 444 MBq (8-12 mCi). For pediatric patients, 1.85 MBq/kg (0.05 mCi/kg) is recommended. Physiologic renal excretion results in visualization of the kidneys and bladder. Rapid absorption by the stomach and peritoneum makes Tc-99m sodium pertechnetate unsuitable for oral or intraperitoneal administration [15].

#### 8. Tc-99m SC

Tc-99m SC, when administered orally, is not absorbed and is an excellent radiopharmaceutical for imaging and quantification of numerous parameters of swallowing and gastrointestinal motility and transit. A small volume (up to 1 mL) of Tc-99m SC containing no more than 18.5 MBq (0.5 mCi) can be used for gastropharyngeal aspiration imaging. In adults, 10 to 30 mL of water containing 3.7 to 11.1 MBq (0.1-0.3 mCi) of Tc-99m SC or Tc-99m DTPA can be given for esophageal transit studies [16]. For gastric emptying, an administered activity of 18.5 to 74 MBq (0.5-2 mCi) is generally used as a

radiolabel for liquid and solid meals in adults. The affinity of this radiopharmaceutical for the protein matrix of egg whites facilitates the egg white labeling as the solid phase component of the meal [17]. There is no weight-based dosage for children, but 9.25 to 37 MBq (0.25-1.0 mCi) can be used to label a liquid meal and 9.25 to 18.5 MBq (0.25-0.5 mCi) for a solid meal.

When administered IV, Tc-99m SC is also utilized for functional imaging of the RES of the liver, spleen, and bone marrow. Tc-99m SC consists of particles composed of Tc-99m sulfide stabilized with gelatin. These particles range in size from 0.1 to 1.0  $\mu\text{m}$ . Given IV, they are phagocytized by the RES cells of the liver, spleen, and bone marrow in proportion to relative blood flow, functional capacity of the phagocytic cells, and particle size. Maximum concentration in the liver and spleen occurs within 10 to 20 minutes, and the rate of biologic clearance from the RES is very slow. The usual administered activity is 111 to 222 MBq (3-6 mCi) for planar imaging in adults and up to 370 MBq (10 mCi) for SPECT imaging.

If administered intraperitoneally, Tc-99m SC is not absorbed and becomes a qualitative marker of movement of ascitic fluid through congenital or traumatic diaphragmatic fenestrations and peritoneovenous shunts. It can be used to assess for free flow or loculation prior to P32 colloidal therapy for malignant ascites. The administered activity of 18.5 to 185 MBq (0.5-5.0 mCi) Tc-99m SC is used [12].

Although less superior to Tc-99m RBCs (autologous), Tc-99m SC can also be utilized to identify a gastrointestinal bleed.

## B. Imaging and Patient Preparation

### 1. Gastrointestinal Imaging

#### a. Salivary Gland

Salivary gland imaging may help in the differential diagnosis of salivary gland disorders and certain masses. A sialogogue, such as lemon juice, may be given to stimulate salivary gland emptying in cases of salivary duct obstruction or ligation, sialadenitis, or suspected Warthin's tumor. The collimator surface should be protected from contamination by using a plastic-backed pad or other similar material. The patient should lie supine in a Water's position in front of a gamma camera (chin and nose touching the collimator). During the IV administration of Tc-99m sodium pertechnetate, a 1-to-2-minute radionuclide angiogram of the face (3-5 seconds/frame) is followed by serial dynamic imaging for 20 to 30 minutes (2-3 minutes/frame). Additional planar views may also be obtained in the oblique and lateral projections as needed [18]. The position of palpable nodules should be identified using a radioactive source marker. Computer-generated regions of interest can be drawn over the salivary glands to produce time-activity curves to demonstrate the pattern of accumulation and clearance over time. Quantitative analysis can be applied to the time-activity curves [16].

### 2. Gastrointestinal Transit

#### a. Aspiration (Gastric or Pharyngeal Contents)

These examinations are usually limited to pediatric patients or as a preoperative pulmonary evaluation prior to lung transplantation. The patient should have nothing by mouth or by tube-feeding prior to the study. The length of time that the patient should refrain from intake depends upon the patient's age and the clinical circumstances, but in most cases, 4 hours should be sufficient. The patient should be in the supine position, and images should include the mouth and stomach in the field of view (FOV). Radioactive source markers are placed for anatomic reference (eg, shoulder markers as reference of the relative location of the lungs). An alternative for pediatric patients is administration of a radiolabeled liquid meal at bedtime

with imaging performed the following morning [19].

i. Aspiration of pharyngeal contents

A small volume of activity of Tc-99m SC is placed on the dorsal surface of the posterior portion of the tongue or in the buccal fossa. Images are obtained in the posterior projection over the course of 30 to 60 minutes. Delayed images can also be acquired up to 24 hours. Radioactivity detected in the bronchi or lungs confirms aspiration.

ii. Aspiration of gastric contents

An appropriate amount of Tc-99m SC is placed in a small amount of the patient's feeding, administered orally or by tubing (nasogastric, gastrostomy) depending on the clinical situation and in consultation with the referring provider. If the material is administered orally, once the feeding is completed, an additional nonradioactive liquid feeding is given to clear any remaining radioactivity from the esophagus. Images are obtained immediately after ingestion (baseline), and serially for 60 minutes thereafter. Additional planar imaging at 4 hours or 24 hours may be helpful. In infants and children, evaluation for aspiration of gastric contents is included as a routine component of nuclear gastric emptying and gastroesophageal reflux examinations. Radioactivity seen in the lungs confirms the diagnosis of aspiration. Imaging is terminated after the radioactivity has cleared from the stomach.

b. Esophageal Transit

Scintigraphy of esophageal transit may yield unique and useful physiologic information about esophageal motility in patients with conditions that cause impaired transit of esophageal contents from the pharynx to the stomach (eg, scleroderma, stricture, achalasia) or following therapy for these conditions [20]. This can be by qualitative or quantitative global or regional (dividing the esophagus into thirds) esophageal evaluation. The patient should have nothing by mouth or by tube-feeding prior to the examination. The length of time that the patient should refrain from intake depends on the patient's age and the clinical circumstances, but in most cases, 4 hours is sufficient. The patient typically is studied in the supine position, and data are collected in the anterior projection to include the entire esophagus and proximal stomach in the FOV. As with barium esophagography, use of multiple (up to 6) swallows can increase the sensitivity of the examination in detecting an abnormal swallow. The patient swallows the appropriate administered activity of Tc-99m SC in water or a semisolid as a bolus. The initial rapid bolus transit should be recorded in a dynamic mode of 0.25 to 0.5 seconds per frame up to 30 seconds [21] and reviewed using a cinematic (movie) display to evaluate the bolus transit. Additional data acquisition for up to 10 minutes is also helpful, during which time the patient is asked to perform serial dry swallows to measure clearance from the esophagus and to look for possible gastroesophageal reflux. Comparison of at least one upright and one supine swallow can be helpful to differentiate disorders such as achalasia from scleroderma. Time-activity curves may be generated regionally for the proximal, middle, and distal portions of the esophagus, but visual inspection of the entire cine bolus transit is more important for differentiating the various primary esophageal motor disorders. Esophageal transit time (ETT) is the time from initial bolus entry into the esophagus until clearance of 90% of peak activity [22]. The normal value for esophageal transit time is generally under 14 seconds [16], although each facility should validate its own normal range for its specific technique or closely follow a validated technique and normal range from literature. No significant activity should be in the esophagus after 10 minutes [21,22].

c. Gastroesophageal Reflux

Scintigraphy for gastroesophageal reflux may yield unique and useful physiologic information in patients whose history, signs, or symptoms suggest possible incompetence of the gastroesophageal sphincter associated with acute or chronic reflux of gastric contents into the



esophagus [20]. Observation of gastroesophageal reflux, however, during an esophageal transit examination can be important as an etiology to reflux esophagitis and associated esophageal dysmotility. In infants and children, a gastroesophageal reflux examination (also called milk scan) is often combined with a liquid gastric emptying examination. The patient should have nothing by mouth or by tube-feeding prior to the examination. The length of time that the patient should refrain from intake depends on the patient's age and the clinical circumstances, but in most cases, 4 hours would be sufficient. A liquid consisting of formula, milk, or orange juice containing an appropriate amount of Tc-99m SC is administered orally or by tubing (nasogastric, gastrostomy). If feasible, when the liquid is introduced via an orogastric or nasogastric tube, the tube should be removed prior to image acquisition. The patient is then positioned supine in a left anterior oblique position beneath the gamma camera, and dynamic images (5-10-second frame images) of the esophagus and stomach are obtained for 60 minutes [23]. Further delayed images can also be obtained for gastric emptying and possible aspiration evaluation. It is often appropriate to image small children in a supine position with the gamma camera under the imaging table. In adults, a Valsalva maneuver or an abdominal binder may be of benefit. Use of an abdominal binder is contraindicated in children. The number of recorded reflux events detected during the recording session should include the duration and the proximal extent of reflux. Gastroesophageal reflux greater than 4% is considered abnormal. This is determined by dividing the maximum counts in the esophagus by counts in the stomach at the beginning of the study [16]. The examination may be repeated to assess the effectiveness of medical therapy.

#### d. Gastric Emptying

Evaluation of gastric motility utilizing a radiolabeled meal provides functional information that is indispensable in the management of patients presenting with various upper gastrointestinal signs and symptoms [24]. The patient should have nothing by mouth or by tube-feeding prior to the examination. This is typically done by instructing the patient to have nothing by mouth overnight prior to the examination. The patient's glucose level should be below 200 mg/dL. Prokinetics and medications that delay gastric emptying must be discontinued 2 days prior to the examination [25]. Three approaches are used: liquid phase, solid phase, and combined liquid-solid phase. In general, the liquid phase is preferred in infants and in neurologically impaired children, whereas the solid phase is used when the patient is capable of ingesting solid food. In both cases, the "meal" needs to be introduced into the stomach fairly quickly (ie, within 10 minutes). It is a good general practice to cover the camera detectors with protective wrap to prevent contamination. A large FOV camera should be used to include the distal esophagus, entire stomach, and proximal small bowel. A region of interest (ROI) is drawn around the stomach, and the counts are decay-corrected. The gastric emptying time-activity curves, half-time of emptying and/or percent of emptying are provided. Anterior posterior imaging to provide for geometric mean attenuation correction should be applied [26]. Posterior projection imaging only may be sufficient in children. Currently, there are no published standardized protocols or normal values for pediatric examinations, and there is a lack of age-related normal values [27].

#### i. Solid-phase meal gastric emptying in adults

The Consensus Recommendations for Gastric Emptying Scintigraphy: a Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine [28] details recommendations for normal values, patient preparation, image acquisition, and data processing. The ACR supports adoption of the recommendations of this consensus guideline and recommends adoption of its recommended normal values, patient preparation, image acquisition, and data processing. Various solid meals have been evaluated. However, the standardized solid radiolabeled meal per consensus guidelines published in 2008 consists of Tc-99m SC mixed and cooked in 120 g of scrambled liquid egg whites and then ingested along with 2 slices of white toast with 30 g of strawberry jelly and 120 mL of water [29]. Subsequently, 1-minute static imaging at

0, 1, 2, and 4 hours is performed with the patient upright. A dual-head gamma camera can be used in order to obtain simultaneous anterior and posterior projections [17,25]. Alternatively, the patient can rotate from an anterior image to a posterior image if a dual-head camera is not available. The geometric mean of the anterior and posterior counts is calculated from a ROI drawn over the stomach. The percentage remaining at each time point is compared with established normal ranges to determine the presence or absence of gastroparesis. Details can be found in the appendix to the consensus guideline, Consensus Recommendations for Gastric Emptying Scintigraphy: a Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine [28].

ii. Liquid-phase gastric emptying in adults and children

Liquids may detect abnormal gastric emptying in some patients when solid gastric emptying scintigraphy is normal. The liquid-phase study can be performed on a separate day, immediately before or concurrently with a solid-phase study. Tc-99m SC (alternatively, Tc-99m DTPA or In-111 DTPA) is mixed with an appropriate volume of a liquid carrier and introduced into the stomach by swallowing or tubing (nasogastric, orogastric, or gastric depending on the clinical situation) and in consultation with the referring clinician. In adults, the liquid meal typically consists of the radiopharmaceutical mixed in 300 mL of water. Imaging with a single-head gamma camera in the left anterior oblique projection is performed over the course of 30 to 60 minutes (1-minute frames continuously). A geometric mean should also be calculated for a liquid meal study [25]. In adult patients, the liquid meal exits from the stomach in a monoexponential fashion. In children, imaging is usually performed during the first hour, and the percentage of emptying is obtained at 60 minutes or later, if indicated. For normal values, details can be found in a 2009 publication by Ziessman et al [26].

iii. Liquid-phase gastric emptying in infants

Liquid-phase gastric emptying may be combined with evaluation of esophageal motility, gastroesophageal reflux, and aspiration. The radiopharmaceutical esophagram may be performed initially or following the completion of the gastric emptying portion of the examination. For the esophagram, the patient is placed in the supine position with the gamma camera posteriorly positioned. Dynamic images of the esophagus at 5 seconds/frame for 2 to 3 minutes are obtained for evaluation of esophageal motility and possible aspiration. If the patient is normally fed by mouth, this may be accomplished as the initial part of the gastric emptying procedure that is then followed by continuous imaging of the chest and abdomen for 60 minutes for evaluation of the presence and severity of gastroesophageal reflux. Gastric emptying at 60 minutes and at 2 or 3 hours after completion of feeding is calculated. If the patient is not orally fed, the esophagram should be performed at the end of the gastric emptying examination using a small volume of radiolabeled sterile water or saline.

iv. Combined liquid- and solid-phase gastric emptying

For this purpose, In-111 DTPA should be utilized for the liquid meal portion of the study, and Tc-99m SC for the solid meal portion [19,30].

e. Intestinal Transit (Small and/or Large Bowel)

Although small- and/or large-bowel transit can be performed separately or in conjunction with gastric emptying scintigraphy, they are most commonly combined with a radiolabeled solid-liquid gastric emptying examination. Medications that may affect transit should be discontinued prior to the examination. No change in diet is necessary. These scans are not commonly performed in pediatric patients. The imaging FOV should include the entire area of interest if possible.



i. Small-bowel transit

This study is performed to evaluate for possible dysmotility of the small bowel. Tc-99m SC or Tc-DTPA in water can be utilized for a single-isotope study. Imaging occurs over 6 hours and is considered normal if > 40% of the radiolabeled liquid has progressed into the terminal ileum reservoir and/or progressed beyond the terminal ileum into the cecum and colon [31].

ii. Large-bowel transit

This study is most commonly utilized for evaluation of constipation or for the effectiveness of prokinetic medications. In-111 DTPA is the preferred radiopharmaceutical for this purpose (Ga-67 is an alternative). Images may be acquired at 6, 24, 48, and 72 hours. At each time point, anterior and posterior abdominal images are obtained for 4 minutes. The geometric-mean-center technique is the most widely used to determine regional transit through the colon. The colon is divided into either 5 or 7 segments, and each is given a numeric value. A geometric center, as a weighted average of the counts in each of these segments, is determined in order to determine progression of the radioactivity in the colon. Higher values indicate activity is mostly in the left colon, and lower values indicate activity is closer to the cecum. Reference values can be found in the publication by Watersham et al [11,32]. Technique details are also published by Maurer et al [10].

iii. Whole-gut transit

An advantage provided by this technique includes the ability to measure solid/liquid gastric emptying in addition to measurement of small-bowel and colon transit resulting in evaluation of the entire gut [10]. A Tc-99m SC-labeled solid meal is given with an In-111 DTPA-labeled liquid meal (water). Gastric emptying and small-bowel transit imaging occurs on day 1, and large-bowel transit typically occurs at 6, 24, 48, and 72 hours. The longer half-life of In-111 DTPA allows for transit evaluation through the colon [31].

### 3. Gastrointestinal Bleeding

a. Acute Gastrointestinal Bleeding

Diagnosis and localization of an active bleeding site requires that the patient be actively bleeding and imaged during the time the radiopharmaceutical is present in the blood pool. Although this procedure is generally used for gastrointestinal bleeding, it can be useful for other sites of active bleeding. The use of Tc-99m RBCs (autologous) is the recommended method because they remain intravascular and permit a longer imaging time. The clinical detection rate for a gastrointestinal bleed with Tc-99m RBCs can be as low as 0.04 mL/min [26]. Tc-99m SC is an alternative radiopharmaceutical but is less superior to Tc-99m RBCs for this purpose, and if utilized, imaging is usually performed for 20 to 30 minutes because of the rapid clearance of SC from the intravascular space. No patient preparation is required. The patient should void immediately before imaging. The radiolabeled cells are injected IV and dynamic imaging of the anterior abdomen is then performed to first include a blood flow/angiographic phase (rate of 1 frame per 1-3 seconds for 60 seconds) and then for another 60 to 120 minutes (preferably 1 frame per 10-20 seconds) [13]. Oblique, lateral, or delayed static abdominal images may be obtained to supplement the basic examination. If the examination is negative, continued imaging may be appropriate for up to 24 hours. SPECT/CT, although not routinely performed, can be of value to more definitively localize the site of bleeding. If gastric activity is noted, further static images of the head and neck can be acquired to assess for possible thyroid and salivary gland uptake to help differentiate between gastric bleeding versus the presence of free pertechnetate.

b. Ectopic Gastric Mucosa (Meckel's Scan)

Pharmacologic enhancement prior to radiopharmaceutical administration with H2 blockers

(cimetidine, famotidine, or ranitidine) or proton pump inhibitors (omeprazole) to enhance free pertechnetate retention and/or glucagon to decrease gastrointestinal peristalsis can be used. Although not required, the patient should fast for 3 to 4 hours prior to imaging to increase sensitivity for detection of ectopic gastric mucosa. The radiopharmaceutical Tc-99m pertechnetate is given IV, and then dynamic imaging of the abdomen is performed. A rapid sequence of images (blood flow/angiographic phase) taken at 1 to 3 seconds per frame over 60 seconds is obtained in the anterior projection to evaluate the presence of hypervascular abdominal lesions that could be mistaken for ectopic gastric mucosa. Subsequent imaging for 30 to 60 minutes is then acquired as serial static views or continuous dynamic imaging (30-60 seconds per image). Continuous dynamic imaging is preferred to better visually discriminate normal physiologic activity (such as renal activity) from ectopic gastric mucosa. A lateral view can be useful to distinguish renal activity and identify retrovesical ectopic gastric mucosa. Additional SPECT/CT imaging may help localization. Prone or right anterior oblique positioning can be used to delay gastric emptying into the small bowel if the patient has not been pretreated with H<sub>2</sub> blockers. A urinary catheter or administration of 1 mg/kg of IV furosemide may be needed to help clear activity from the ureters and bladder [14].

#### 4. Peritoneal Imaging

No specific preprocedure patient preparation is required. A local anesthetic may be administered prior to injection of the radiopharmaceutical.

##### a. Evaluation of patency of peritoneovenous shunt

Tc-99m SC or Tc-99m MAA is directly administered into the peritoneal cavity using aseptic technique. An immediate image of the abdomen may be helpful to determine whether the radiopharmaceutical is free in the peritoneum and not loculated. The patient may need to roll from side to side to mix the radioactivity within the ascites. Also, normal saline (50-200 mL) can be infused intraperitoneally to facilitate distribution. Static anterior images are typically acquired at 10, 30, 60, and 120 minutes. If the shunt is functioning correctly, activity will eventually appear in the liver and spleen (with Tc-99m SC) or lungs (with Tc-99m MAA) over 1 to 2 hours. Activity in the shunt tubing may or may not be visualized [12,33].

##### b. Detection of congenital fenestrations or traumatic perforations of the diaphragm

Tc-99m SC or Tc-99m MAA is administered intraperitoneally. The radiopharmaceutical can also be instilled with up to 500 mL of sterile normal saline in order to facilitate movement of the radiopharmaceutical into the pleural cavity. If activity appears in the pleural space, the diagnosis of fenestrated or perforated diaphragm is confirmed [34-36].

##### c. Demonstration of peritoneal loculation of fluid

Tc-99m SC or Tc-99m MAA is administered intraperitoneally. Immediate and delayed static images over the abdomen will reveal the pattern of distribution of the radiopharmaceutical in the peritoneal cavity.

#### C. Liver and Spleen Imaging

##### 1. Assess size, shape, and/or position of the liver and/or spleen

Tc-99m SC can be used to identify the size and location of functional hepatic and splenic tissue. Approximately 10 to 20 minutes after IV administration of Tc-99m SC, static planar images of the liver and spleen are obtained. Anterior, posterior, right anterior oblique (RAO), left anterior oblique (LAO), right posterior oblique (RPO), and right lateral images should be acquired. Additional views (left posterior oblique [LPO] and left lateral) may be indicated for more comprehensive evaluation of the spleen. Another anterior image may also be acquired with a lead marker of known length to help determine organ sizes. Additional SPECT or SPECT/CT localizes any focal abnormality seen on planar

imaging. The normal distribution of Tc-99m SC in the RES is approximately 85% to the liver, 10% to the spleen, and 5% to the bone marrow. A shift away from the normal biodistribution can be seen in severe liver dysfunction and is termed "colloid shift" in which there is greater splenic and marrow uptake [37].

## 2. Differentiation of hepatic or splenic hemangiomas and other mass lesions

Hepatic or splenic hemangiomas are conspicuous with Tc-99m RBCs imaging because of their relatively greater blood volume than that of the surrounding parenchyma. They are typically identified when the radiolabeled RBCs reach equilibrium within the intravascular space of the hemangioma, which may take between 30 and 120 minutes postinjection or longer (may require up to 24 hours or more for larger hemangiomas [12]). Following IV administration of Tc-99m RBCs (autologous), immediate angiographic images (1-second intervals for 60 seconds) may yield useful information on the vascularity of particular lesions. Hemangiomas show typical low flow in the arterial phase with late "filling in" on delayed images. This is followed by blood pool imaging (eg, delayed imaging). SPECT or SPECT/CT imaging is particularly helpful in identifying lesions smaller than 3 cm.

Depending upon whether there are functioning or nonfunctioning Kupffer cells, the uptake pattern with Tc-99m SC can help differentiate between different types of mass lesions in the spleen and liver. Types of photopenic lesions include infarcts, cysts, hepatic adenoma, etc. FNH typically has increased uptake in the liver [16]. Up to 30% FNH will be photopenic on a liver scan.

## 3. Evaluating for residual or ectopic functioning splenic tissue and suspected functional asplenia

The radiopharmaceutical Tc-99m RBCs (autologous and heat damaged) is administered IV (preparation technique in Welch et al [38]). Imaging of the abdomen may commence 30 to 120 minutes later. Planar and SPECT or SPECT/CT imaging parameters are similar to those for liver and spleen imaging. If the test is being performed to identify residual or ectopic splenic tissue, the abdomen and pelvis should be imaged. If the patient has had prior trauma that might have ruptured the diaphragm, the chest should be imaged as well. Alternatively, Tc-99m SC can be utilized instead, but it is less sensitive and specific as compared with Tc-99m heat-damaged RBCs [12].

## V. DOCUMENTATION

Reporting should be in accordance with the [ACR Practice Parameter for Communication of Diagnostic Imaging Findings](#) [39].

The report should include the radiopharmaceutical used, the administered activity, and the route of administration as well as any other pharmaceuticals administered, including their dose and route of administration.

## VI. EQUIPMENT SPECIFICATIONS

Equipment performance monitoring should be in accordance with the [ACR–AAPM Technical Standard for Nuclear Medical Physics Performance Monitoring of Gamma Cameras](#) [40].

A gamma camera with a low-energy all purpose (LEAP) or high-resolution collimator is used for Tc-99m–labeled radiopharmaceuticals. A medium-energy collimator is needed for In-111 and Ga-67. SPECT or SPECT/CT may also be useful in select cases.

## VII. RADIATION SAFETY

Radiologists, medical physicists, non-physician radiology providers, radiologic technologists, and all supervising physicians have a

responsibility for safety in the workplace by keeping radiation exposure to staff, and to society as a whole, "as low as reasonably achievable" (ALARA) and to assure that radiation doses to individual patients are appropriate, taking into account the possible risk from radiation exposure and the diagnostic image quality necessary to achieve the clinical objective. All personnel who work with ionizing radiation must understand the key principles of occupational and public radiation protection (justification, optimization of protection, application of dose constraints and limits) and the principles of proper management of radiation dose to patients (justification, optimization including the use of dose reference levels). [https://www-pub.iaea.org/MTCD/Publications/PDF/PUB1775\\_web.pdf](https://www-pub.iaea.org/MTCD/Publications/PDF/PUB1775_web.pdf)

Facilities and their responsible staff should consult with the radiation safety officer to ensure that there are policies and procedures for the safe handling and administration of radiopharmaceuticals in accordance with ALARA principles. These policies and procedures must comply with all applicable radiation safety regulations and conditions of licensure imposed by the Nuclear Regulatory Commission (NRC) and by applicable state, local, or other relevant regulatory agencies and accrediting bodies, as appropriate. Quantities of radiopharmaceuticals should be tailored to the individual patient by prescription or protocol, using body habitus or other customized method when such guidance is available.

Nationally developed guidelines, such as the [ACR's Appropriateness Criteria](#)<sup>®</sup>, should be used to help choose the most appropriate imaging procedures to prevent unnecessary radiation exposure.

Additional information regarding patient radiation safety in imaging is available from the following websites – Image Gently<sup>®</sup> for children ([www.imagegently.org](http://www.imagegently.org)) and Image Wisely<sup>®</sup> for adults ([www.imagewisely.org](http://www.imagewisely.org)). These advocacy and awareness campaigns provide free educational materials for all stakeholders involved in imaging (patients, technologists, referring providers, medical physicists, and radiologists).

Radiation exposures or other dose indices should be periodically measured by a Qualified Medical Physicist in accordance with the applicable ACR Technical Standards. Monitoring or regular review of dose indices from patient imaging should be performed by comparing the facility's dose information with national benchmarks, such as the ACR Dose Index Registry and relevant publications relying on its data, applicable ACR Practice Parameters, NCRP Report No. 172, Reference Levels and Achievable Doses in Medical and Dental Imaging: Recommendations for the United States or the Conference of Radiation Control Program Director's National Evaluation of X-ray Trends; 2006, 2009, amended 2013, revised 2023 (Res. 2d).

## **VIII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION**

Policies and procedures related to quality, patient education, infection control, and safety should be developed and implemented in accordance with the ACR policy on Quality Control Improvement, Safety, Infection Control, and Patient Education appearing under the heading *ACR Position Statement on Quality Control and Improvement, Safety, Infection Control and Patient Education* on the ACR website (<https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Quality-Control-and-Improvement>).

### **ACKNOWLEDGEMENTS**

This practice parameter was revised according to the process described under the heading *The Process for Developing ACR Practice Parameters and Technical Standards* on the ACR website (<https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards>) by the Committee on Practice Parameters and Technical Standards – Nuclear Medicine and Molecular Imaging of the ACR Commission on Nuclear Medicine and Molecular Imaging and the Committee on Practice Parameters – Pediatric Radiology of the ACR Commission on Pediatric Radiology in collaboration with the ACNM, the SNMMI, and the SPR.

Writing Committee – members represent their societies in the initial and final revision of this practice parameter

#### ACR

#### ACNM

Twyla B. Bartel, DO, MBA, Chair

Erin C. Grady, MD

Writing Committee – members represent their societies in the initial and final revision of this practice parameter

Shana Elman, MD

Darlene F. Metter, MD, FACR

Helen R. Nadel, MD

SNMMI

David Brandon, MD

Saeed Elojeimy, MD, PhD

Alan Maurer, MD

Mark Tulchinsky, MD, FACNM, CCD

SPR

Hollie A. Lai, MD

Sachin Kumbhar, MD

Neha Kwatra, MD

Nadia F. Mahmood, MD

Jennifer L. Williams, MD

Committee on Practice Parameters and Technical Standards – Nuclear Medicine and Molecular Imaging

(ACR Committee responsible for sponsoring the draft through the process)

Kevin P. Banks, MD, Co-Chair

Andrew Kaiser, MD

Richard K. J. Brown, MD, FACR, Co-Chair

Jeffrey S. Kempf, MD, FACR

Munir V. Ghesani, MD, FACR, Co-Chair Vice Chair

Jennifer J. Kwak, MD

Rathan M. Subramaniam, MD, PhD, MPH, Co-Chair Vice Chair

Justin G. Peacock, MD

Esma A. Akin, MD, FACR

Syam P. Reddy, MD

Alexandru C. Bageac, MD, MBA

Eric M. Rohren, MD, PhD

## Committee on Practice Parameters and Technical Standards – Nuclear Medicine and Molecular Imaging

(ACR Committee responsible for sponsoring the draft through the process)

Twyla B. Bartel, DO, MBA

Levi Sokol, MD

Elizabeth H. Dibble, MD

Andrew T. Trout, MD

K. Elizabeth Hawk, MD, MS, PhD

Stephanie P. Yen, MD

Eric Hu, MD

## Committee on Practice Parameters – Pediatric Radiology

(ACR Committee responsible for sponsoring the draft through the process)

Beverley Newman, MB, BCh, BSc, FACR, Chair

Jason Higgins, DO

Terry L. Levin, MD, FACR, Vice Chair

Jane Sun Kim, MD

John B. Amodio, MD, FACR

Jessica Kurian, MD

Tara M. Catanzano, MB, BCh

Matthew P. Lungren, MD, MPH

Harris L. Cohen, MD, FACR

Helen R. Nadel, MD

Kassa Darge, MD, PhD

Erica Poletto, MD

Dorothy L. Gilbertson-Dahdal, MD

Richard B. Towbin, MD, FACR

Lauren P. Golding, MD

Andrew T. Trout, MD

Safwan S. Halabi, MD

Esben S. Vogelius, MD

Don C. Yoo, MD, FACR, Chair of the Commission Nuclear Medicine and Nuclear Medicine



Richard A. Barth, MD, FACR, Chair, Commission on Pediatric Radiology

Jacqueline Anne Bello, MD, FACR, Chair, Commission on Quality and Safety

Mary S. Newell, MD, FACR, Chair, Committee on Practice Parameters and Technical Standards

#### Comments Reconciliation Committee

Kurt Schoppe, MD, Chair

Sachin Kumbhar, MD

Aradhana Venkatesan, MD Co-Chair

Neha Kwatra, MD

Kevin P. Banks, MD

Hollie A. Lai, MD

Twyla B. Bartel, DO, MBA

Paul A. Larson, MD, FACR

Richard A. Barth, MD, FACR

Terry L. Levin, MD, FACR

Jacqueline Anne Bello, MD, FACR

Nadia F. Mahmood, MD

Pradeep G. Bhambhani, MD

Alan Maurer, MD

David Brandon, MD

Darlene F. Metter, MD, FACR

Richard K.J. Brown, MD, FACR

Helen R. Nadel, MD

Richard Duszak Jr., MD, FACR

Mary S. Newell, MD, FACR

Shana Elman, MD

Beverley Newman, MB, BCh, BSc, FACR

Saeed Elojeimy, MD, PhD

Rathan M. Subramaniam, MD, PhD, MPH

Munir V. Ghesani, MD, FACR

Mark Tulchinsky, MD, FACNM, CCD

Erin C. Grady, MD

Jennifer L. Williams, MD

Amy L. Kotsenas, MD, FACR

Don C. Yoo, MD, FACR

#### **REFERENCES**

**1. [16818960]** Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure Guideline for SPECT/CT Imaging 1.0. J Nucl Med. 2006 Jul;47(7):1227-34.

2. [-3197670] American College of Radiology. ACR–ACNM–SNMMI–SPR Practice Parameter for the Performance of Hepatobiliary Scintigraphy. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=126+&releaseId=2>
3. [-3197656] American College of Radiology. ACR–ABS–ACNM–SIR–SNMMI Practice Parameter for Selective Internal Radiation Therapy (SIRT) or Radioembolization for Treatment of Liver Malignancies. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=32+&releaseId=2>
4. [-3197674] American College of Radiology. ACR–ACNM–SNMMI–SPR Practice Parameter for the Use of Radiopharmaceuticals in Diagnostic Procedures. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=171+&releaseId=2>
5. [-3120926] American College of Radiology. ACR-SPR Practice Parameter for Imaging Pregnant or Potentially Pregnant Patients with Ionizing Radiation. Available at: <https://gravitas.acr.org/PPTS/GetDocumentView?docId=23+&releaseId=2>.
6. [27909182] Treves ST, Gelfand MJ, Fahey FH, Parisi MT. 2016 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities. *J Nucl Med*. 2016 Dec;57(12):15N-18N.
7. [23329525] Aslil NINDepartment of Nuclear Medicine, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran., EhsaniM JMJ, JavadiHH, SemnaniSS, TabibS MSM, AssadiMM. Comparison of three with six regions of interest analyses in patients with idiopathic constipation undertaking colon transit scintigraphy using 67Ga-citrate. *Eur Rev Med Pharmacol Sci* 17:69-74, .
8. [10025835] BartholomeuszDDDDepartment of Nuclear Medicine, Royal Adelaide Hospital, South Australia, Australia., ChattertonB EBE, BellenJ CJC, GaffneyRR, HunterAA. Segmental colonic transit after oral 67Ga-citrate in healthy subjects and those with chronic idiopathic constipation. *J Nucl Med* 40:277-82, .
9. [29622808] Keller J, Bassotti G, Clarke J, et al. Expert consensus document: Advances in the diagnosis and classification of gastric and intestinal motility disorders. *Nat Rev Gastroenterol Hepatol*. 2018 May;15(5):291-308.
10. [24092937] Maurer AH, Camilleri M, Donohoe K, et al. The SNMMI and EANM practice guideline for small-bowel and colon transit 1.0. *J Nucl Med*. 2013 Nov;54(11):2004-13.
11. [-3197818] Waterstram-Rich K, Christian PE. Nuclear Medicine and PET/CT E-Book: Technology and Techniques. 7th ed: Elsevier Health Sciences; 2013.
12. [-3197819] Elgazzar AH, Sarikaya E. Nuclear Medicine Companion: A case-based practical reference for daily use: Springer; 2018.
13. [25472517] Dam HQ, Brandon DC, Grantham VV, et al. The SNMMI procedure standard/EANM practice guideline for gastrointestinal bleeding scintigraphy 2.0. *J Nucl Med Technol*. 2014 Dec;42(4):308-17.
14. [26678616] Grady E. Gastrointestinal Bleeding Scintigraphy in the Early 21st Century. *J Nucl Med*. 2016 Feb;57(2):252-9.
15. [-3197820] International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. *Ann ICRP* 1988;18:1-4.
16. [-3107819] Mettler Jr FA, Guiberteau MJ. 8 - Skeletal System. *Essentials of Nuclear Medicine Imaging* (Sixth Edition). Philadelphia: W.B. Saunders; 2012:271-314.
17. [10894578] Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. *Am J Gastroenterol*. 2000 Jun;95(6):1456-62.
18. [19223429] MacDonald A, Burrell S. Infrequently performed studies in nuclear medicine: part 2. *J Nucl Med Technol*. 2009 Mar;37(1):1-13.
19. [16517233] Maurer AH, Parkman HP. Update on gastrointestinal scintigraphy. *Semin Nucl Med*. 2006 Apr;36(2):110-8.
20. [19341838] Odunsi ST, Camilleri M. Selected interventions in nuclear medicine: gastrointestinal motor functions. *Semin Nucl Med*. 2009 May;39(3):186-94.
21. [26025963] Maurer AH. Gastrointestinal Motility, Part 1: Esophageal Transit and Gastric Emptying. *J Nucl Med*. 2015 Aug;56(8):1229-38.
22. [25766893] Antoniou AJ, Raja S, El-Khouli R, et al. Comprehensive radionuclide esophagogastrintestinal transit study: methodology, reference values, and initial clinical experience. *J Nucl Med*. 2015 May;56(5):721-7.
23. [29812981] Solnes LB, Sheikhabaei S, Ziessman HA. Nuclear Scintigraphy in Practice: Gastrointestinal Motility. *AJR Am J Roentgenol*. 2018 Aug;211(2):260-266.
24. [23316944] Olausson EA, Brock C, Drewes AM, et al. Measurement of gastric emptying by radiopaque markers in patients with diabetes: correlation with scintigraphy and upper gastrointestinal symptoms. *Neurogastroenterol Motil*. 25(3):e224-32, 2013 Mar.
25. [30285398] Banks KP, Syed K, Parekh M, McWhorter N. Gastric Emptying Scan.
26. [19372480] Ziessman HA, Chander A, Clarke JO, Ramos A, Wahl RL. The added diagnostic value of liquid gastric

emptying compared with solid emptying alone. J Nucl Med. 2009 May;50(5):726-31.

**27. [22349910]** Resolution 16)

**27. [22349910]** Bradburn LA, Kourmouzi V, Cao X, Zurakowski D, Fahey FH. Gastric emptying in children: what is the best acquisition method?. J Pediatr Gastroenterol Nutr. 2012 Aug;55(2):191-3.

**28. [18028513]** Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol. 2008 Mar;103(3):753-63.

**29. [19692450]** Donohoe KJ, Maurer AH, Ziessman HA, et al. Procedure guideline for adult solid-meal gastric-emptying study 3.0. J Nucl Med Technol. 2009 Sep;37(3):196-200.

**30. [21365240]** Sachdeva P, Malhotra N, Pathikonda M, et al. Gastric emptying of solids and liquids for evaluation for gastroparesis. Dig Dis Sci. 2011 Apr;56(4):1138-46.

**31. [26159586]** Maurer AH. Gastrointestinal Motility, Part 2: Small-Bowel and Colon Transit. J Nucl Med. 2015 Sep;56(9):1395-400.

**32. [12914559]** Madsen JL, Fuglsang S, Graff J. Reference values for the geometric centre analysis of colonic transit measurements with 111indium-labelled diethylenetriamine penta-acetic acid. Clin Physiol Funct Imaging. 2003 Jul;23(4):204-7.

**33. [24250023]** Gandhi SJ, Babu S, Subramanyam P, Shanmuga Sundaram P. Tc-99m macro aggregated albumin scintigraphy - indications other than pulmonary embolism: A pictorial essay. Indian J Nucl Med. 2013 Jul;28(3):152-62.

**34. [11339424]** Bhattacharya A, Mittal BR, Biswas T, et al. Radioisotope scintigraphy in the diagnosis of hepatic hydrothorax. J Gastroenterol Hepatol. 2001 Mar;16(3):317-21.

**35. [27178806]** Hewett LJ, Bradshaw ML, Gordon LL, Rockey DC. Diagnosis of isolated hepatic hydrothorax using peritoneal scintigraphy. Hepatology. 2016 Oct;64(4):1364-6.

**36. [30700534]** Choudhary G, Manapragada PP, Wallace E, Bhambhani P. Utility of Scintigraphy in Assessment of Noninfectious Complications of Peritoneal Dialysis. J Nucl Med Technol. 2019 Jun;47(2):163-168.

**37. [-3197821]** Zeissman HA, O'Malley J, Thrall J. Nuclear Medicine: The Requisites. 4th ed: Elsevier Saunders; 2014.

**38. [-3197822]** Welch MJ. Radiopharmaceuticals and Other Compounds Labelled with Short-Lived Radionuclides: Elsevier; 2013.

**39. [-3197621]** American College of Radiology. ACR Practice Parameter for Communication of Diagnostic Imaging Findings. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=74+&releaseId=2>

**40. [-3197885]** American College of Radiology. ACR–AAPM Technical Standard for Nuclear Medical Physics Performance Monitoring of Gamma Cameras. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=196+&releaseId=2>